Colorectal cancer studies typically include both colon and rectum tumors as a common entity, though this assumption is controversial and only minor differences have been reported at the molecular and epidemiological level. Here we report a large sample pool study concluding that only minor differences at a gene expression level exist between microsatellite stable colorectal cancers at different locations.
INTRODUCTION
Colorectal cancer (CRC) is considered a heterogeneous complex disease that comprises different tumor phenotypes 1 . Attempts to classify tumors from a molecular perspective that identify carcinogenic pathways have proposed three categories with some overlap: chromosomal instability (CIN) tumors, microsatellite instability (MSI) tumors, and CpG island methylator phenotype (CIMP) tumors. This taxonomy plays a significant role in determining clinical, pathological and biological characteristics of CRC 2 .
From a clinical point of view, the colon and rectal cancers are treated as distinct entities. Colon tumors are usually divided as proximal or right sided when originating proximal to the splenic flexure (cecum, ascending colon, transverse colon) whereas distal tumors arise distal to this site (descending colon and sigmoid colon). Distal colon or left sided tumors most often appear in the rectum-sigmoid flexure and the distinction of these from rectal tumors is not always easy. Usually a tumor is considered rectal when arising within 15 centimeters from the anal sphincter 3,4 . Indeed, accumulating evidences suggest that grouping these anatomically distinct diseases could be a clinical and biological oversimplification:
rectal cancers show higher rates of locoregional relapse and lung metastases, whereas colon cancers have a higher tropism for liver spread and a slightly better overall prognosis 5 . Moreover, proximal location of colon cancer is a risk factor for development of metachronous colorectal cancer 6 .
Treatment also differs for colon and rectal tumors. Although both colon and rectal cancers benefit from adjuvant chemotherapy, radiation therapy is only indicated in locally advanced rectal tumors 7 .
Epidemiologic risk factors reflect somewhat more controversial distinctions between cancers of the colon and rectum: alcohol intake was significantly positively associated with higher risk in the rectum than in colon tumors 8 . Other dietary risk factors differing between colon and rectum tumors have been suggested more inconsistently 9, 10 .
At the molecular level, differences in expression of specific genes and proteins (Cyclin A2, COX2, beta-catenin) have been reported (reviewed in ref. 6). Moreover, colon cancers have a higher number of mutations including KRAS and BRAF mutations. The CIN pathway is far more common in rectal cancers than colon cancers, whereas MSI and CIMP cancers are more likely to be in the right colon.
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MATERIALS AND METHODS

Study population
The Molecular Epidemiology of Colorectal Cancer (MECC) study is a population-based, case-control study that included 2,138 incident CRC cases and 2,049 population controls from Northern Israel 16 . A pathology review of the diagnostic slides centralized at the University of Michigan confirmed the eligibility criteria of invasive adenocarcinoma. The study was approved by the Institutional Review
Boards at the University of Michigan and Carmel Medical Center in Haifa. Written, informed consent was required for inclusion.
A subset of these patients provided fresh tumor tissue samples that were analyzed for expression in two stages as previously described 17 . Initially, a subset of 170 tumors was hybridized with the Affymetrix HG-U133A gene array (MECC-A). In a second stage, an additional sample of 232 tumors was hybridized in the HG-U133plus 2.0 gene array (MECC-P2). Of these patients, four from the first set and seven from the second were excluded because had multiple tumors in the colon and rectum or the precise location was not provided. Expression data are available in Gene Expression Omnibus (GEO) 18 repository with accession code GSE26682.
In addition of these two gene expression datasets (MECC-A and MECC-P2), publicly available expression data with information about sub-site was searched in the GEO and ArrayExpress 19 databases. To guarantee a high-quality analysis, the inclusion criteria was restricted to studies that had used Affymetrix U133 gene chips, with more than 50 samples, and a minimum number of 10 for each site. Two datasets were identified matching these criteria: GSE14333 included 290 consecutive 
Quality control and normalization
Prior to data analysis a careful quality control process following the Affymetrix recommendations was performed 23 . This procedure rejected 122 samples: 27 (16%) from MECC-A, 49 (21%) from MECC-P2, 21 (7%) from GSE14333 and 25 (16%) from GSE13294.
Data normalization was performed using the R statistical software, version 2.9.0 (R foundation for statistical computing; http://www.r-project.org) and Bioconductor package (Bioconductor core group; http://www.bioconductor.org). Raw data from the different datasets were normalized together using the Robust Multiarray Average (RMA) method 24 . In order to improve comparability between arrays from different studies, only the common subset of probes from the U133A array (n= 22,283) were selected and data were renormalized using a quantile method.
Microsatellite instability
Tumors showing MSI appear more often in right colon and are known to have a marked different expression profile 25 . In an attempt to homogenize the analysis and avoid potential biases due to this condition MSI tumors were excluded from all datasets. For MECC cases MSI was analyzed using seven microsatellite markers that included the NCI panel 26 . Cases were considered MSI when more than 30% of the markers were instable. 16 cases were excluded from MECC-A and 15 from MECC-P2. 61 MSI samples from dataset GSE1324 were also excluded.
MSI status was not available for the public GSE14333 dataset, but was imputed using a molecular profiling based approach (details in supplementary material 
Differential expression analysis
Prior to the identification of differentially expressed probes, a filter was applied in order to remove those with low variability (n=7,509), which mostly correspond to non-hybridized and saturated probes.
The remaining 14,774 probes with standard deviation greater than 0.3 were considered for further analysis. In order to test for differences in expression between sites, a linear model adjusted for gender, age and study was fitted to each probe. To account for multiple comparisons, the Bonferroni correction was used. Also the less conservative q-value method was used to control the false discovery rate (FDR).
Heterogeneity of expression profiles by tumor site across studies was evaluated for each probe using the linear models described above. A test for interaction between cancer site and study was performed for each probe and, again, the q-value method was used to correct the results by multiple comparisons.
Gene set enrichment analysis
The GSEA algorithm 27 was applied to identify enrichment of specific functions in the list of genes preranked according to their p value for the test of differences in expression between sub-sites. The statistical significance of the enrichment score was calculated by permuting the genes 1,000 times as implemented in the GSEA software.
Classification of colon / rectum samples using differentially expressed genes
For each comparison considered, an agglomerative hierarchical clustering method was used in order to display the classification ability among site of the corresponding list of differentially expressed probes sets. This discriminating ability was formally tested using a linear discriminant analysis with leave-one-out cross-validation to estimate the prediction error rate.
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RESULTS
Clinical data for the 460 colon tumors and 100 rectum tumors included in the analysis are summarized in Table I . A principal component analysis (PCA) was done to assess global differences between each dataset. The first and second components separated the samples by study, suggesting systematic differences that could not be corrected by careful homogeneous criteria and normalization (Supplementary Figure 2) . The most dissimilar dataset was MECC-A, probably due to be the fact that the platform was Affymetrix H-U133 A gene chips, instead of H-U133 Plus 2.0 used in the other studies. All pooled analyses were adjusted for study to account for these systematic differences.
Gene expression profiling: colon versus rectum tumors
Linear models adjusted for study, age and gender identified only 11 out of 14,774 differentially expressed probes between colon and rectum after Bonferroni correction. The less conservative qvalue method identified 20 probes (corresponding to 16 genes, Table II ) when a 1% FDR was used, and 131 probes (111 genes) at the 5% FDR. Moreover, among these differentially expressed genes, no one had an absolute log2 fold change larger than 1 (Figure 1 A) . These results suggest that the magnitude of expression differences among microsatellite stable (MSS) tumors arising in the colon and rectum is quite small. Functionally, it was noteworthy that five of the top six genes belonged to the HOX family of transcription factors (Table II) . Other top differentially expressed genes displayed assorted functions such as DNA repair, transcription factor activity, intracellular transport, signal transduction and apoptosis among others. To formally identify enriched biological processes associated with differentially expressed genes a GSEA was done. Although no significant function was retrieved, the "HOX genes" set appeared with the highest gene enrichment score (Supplementary Figure 3) .
Heterogeneity across studies was explored to identify genes that might have differences in some studies but opposite direction in others that might compensate in the pooled analysis. Only 12 probes showed heterogeneity between studies at the 5% FDR and these could not be ascribed to a systematic effect of one specific study (Supplementary Figure 4) . None of these 12 heterogeneous probes corresponded to differentially expressed genes. Therefore, the four studies included in our analysis were considered homogeneous regarding their differences in expression profiles between colon and rectum.
Refining gene expression profiling: right colon versus left colon tumors and right colon versus rectum tumors
To discount the possibility that similar molecular backgrounds in left colon and rectum tumors were masking possible differences between total colon samples and rectum tumors, a more detailed analysis was performed looking for differences between right colon, left colon and rectum tumors, when detailed data about cancer site were available (n = 499, all datasets except GSE13294).
Similar to previous results, no major differences were detected between right and left colon, reinforcing our impression that microsatellite stable colorectal tumors show very similar expression profiles regardless of their site of origin. Ten genes were found to be differentially expressed between right and left colon tumors after Bonferroni correction. The q-value method only identified 44 probes differentially expressed corresponding to 40 genes at 1% FDR (Table III) and 174 probes (150 genes) at 5% FDR. Interestingly, the comparison between left colon and rectum did not identify any differentially expressed gene at 1% FDR (only 3 genes were found at FDR 5%). In contrast, 54 probes (50 genes) were differentially expressed between right-colon and rectum when a 1% FDR was used (Table IV) To assess the ability of these profiles to discriminate cancer samples by location, a linear discriminant analysis model was built. Leave-one out internal validation showed that only 37% of rectum tumors were correctly classified when using the colon versus rectum signature ( Since classification of rectal tumors is controversial and misclassification could exist between rectal and sigmoid colon tumors, an analysis in which rectal and left-sided colon cancers were pooled and compared with right-sided colon cancer was also performed. As a result, 46 probes corresponding to 35 genes were found to be differentially expressed after Bonferroni correction. The q-value method identified 256 probes (202 genes) differentially expressed at 1% FDR (Supplementary Table III) and 884 probes at 5% FDR. Though this comparison showed a larger number of significant probes, related to the increased sample size of the distal location group, the magnitude of the differences were very small (<10%) and probably not biologically relevant.
HOX genes
Remarkably, HOX appeared as the most differentially expressed genes in all transcriptomic comparisons and emerged in the intersection of the lists of differentially expressed genes. In fact, these HOX genes were expressed in a gradient in colorectal tumors. The HOX genes were more expressed in tumors from the proximal colon and their expression decreased along more distal locations in the gastrointestinal tract, with the exception of HOXB13 that showed a reversed pattern ( Figure 2 ). Genes known to be targets of HOX transcription factors 28 were analyzed, but these showed no differences in expression between sub-sites indicating that differences observed in HOX genes were not affecting a cascade of regulated genes (Supplementary Figure 5) . Also, specific GSEA analysis using HOX-related gene sets showed a statistically significant enrichment for genes activated by the chimeric protein NUP98-HOXA9, an aberrant HOX transcription factor and also and enrichment in genes with promoter regions around transcription start site containing the motif that binds with Table IV) .
Interestingly, the analysis of expression for HOX genes in human normal colorectal mucosa in the dataset GES9254 showed the same gradient along the gut than in tumor samples (Supplementary Figure 6 ).
DISCUSSION
This pool analysis of four datasets from three independent studies including a total of 560 samples suggests that there are identifiable expression differences among microsatellite stable CRCs that arise in different sites within the large intestine. However, the number of statistically significant differentially expressed genes found between tumor locations was minimal, and the fold change of their expression was within random variation for most cases. With the exception of the HOX family, there were no identifiable functional distinctions among the differentially expressed genes. Moreover, the most evident distinctions in expression profiles were those between the right colon and either the left colon or rectum. Expression profiles of microsatellite stable rectal cancers and right-sided colon cancers were virtually indistinguishable.
These results imply that anatomical differences are relevant for the clinical management of colorectal cancer, but those specific molecular profiles of microsatellite stable CRC are for the large part, quite similar. It is well known that metastases from colorectal cancer develop in a stepwise process 29 .
Rectal cancers usually have a pattern of local recurrence and retrospective studies show a relevant influence of the surgeon on the prognosis of these patients 30 . For colon cancers, the progression pattern is more typically characterized by liver metastases, potentially explained by the fact that superior mesenteric vein drains the right colon whereas neither the left colon nor the rectal vasculature directly drains to liver 29 . One might have hypothesized that molecular differences such as DNA repair, apoptosis or angiogenesis might have distinguished rectal cancers, given the differential efficacy of radiotherapy for rectal cancers. However our study did not reveal any such clues or signatures. The samples that were analyzed were all tumors collected prior to treatment. Although it is possible that expression profiles that predict response to radiotherapy might exist, our pre-treatment data are unable to address this hypothesis. In addition, there is no known evidence of differential radiation sensitivity between colon and rectal cancers. It is only the particular topographic intrapelvic location of the rectum that renders it appropriate for radiotherapy due to the lack of small bowel interaction with the radiation field, which is the limiting factor of the radiotherapy administration in colon cancer 31, 32.
Research. A potential concern of studies that fail to detect differences in expression patterns between tumors is the possibility of insufficient statistical power to detect even clinically or biologically meaningful differences due to a small sample size. To address this issue a pooled analysis has been performed that included a total of 560 samples, enough to detect 0.5 standard deviation units. In practice, most of the few significant genes identified showed fold changes smaller than 0.6 or a 50% variation in expression, which is usually considered small in microarray expression analyses. Small studies also may show apparent differences that are particular to the selection of cases analyzed. The strength of meta-analyses like the one reported here is that only consistent results remain, and these are easily identified since power is larger and heterogeneity can be explored to identify study specificities. In our analysis heterogeneity among studies was not a concern since only 12 probes, out of almost 15,000 explored, showed significant heterogeneity and they could not be ascribed to a specific study.
MSI tumors were not included in the analysis due to their known different molecular background 21, 25, 33 and strong association with tumor location. In the case of GSE14333 dataset, the researchers did not provide information about MSI status so a simple signature-based imputation was done to exclude putative MSI tumors from the analysis. This procedure had its limitations since its accuracy for MSI was only 85% (Supplementary Table I Table II) 34 . Additionally, an analysis excluding GSE14333 dataset was performed and similar results (still less significant genes) were obtained (Supplementary Table V) .
It is worth mentioning that differences between cancer sites previously reported in some studies may has been reported to be more expressed in proximal structures than distal 11 but we didn't found it as a right-side associated gen. However, if we include in our analysis MSI tumors and look for CDX2 expression, it appeared as a differentially expressed gen with a q-value < 0.01. So, the significance of CDX2 is probably due to MSI and not to tumor location.
Although most of CIMP-positive tumors are MSI and therefore were not included in this analysis, there are some CIMP-positive, microsatellite stable tumors that preferentially arise in the right colon 2, 38 which could explain some of the larger differences between the tumors arising in the right colon and other tumors. In an attempt to explore this possibility, a gene expression signature that differentiates MSS CIMP+ and MSS CIMP-colorectal carcinomas was used 39 in a GSEA analysis. This revealed an association between CIMP+ genes and right-sided genes (supplementary figure 7) and suggests that some of the described differences could be related to CIMP phenotype.
Only HOX genes were found to be an enriched set associated with colon tumors. These genes (also activated by NUP98-HOXA9 was found. This is an aberrant HOXA9 transcription factor that promotes the growth of murine hematopoietic progenitors and blocks their differentiation 45 . This result might be related to a possible role of HOX genes in CRC right-side tumor progression that deserves experimentally exploration.
In conclusion, our study strongly suggests that the expression profiles of microsatellite stable
colorectal cancers do not demonstrate major differences for tumors arising in the colon or rectum, and that the small, but consistent differences observed between right-sided and left-sided / rectal cancers are largely driven by the HOX family of genes. Although it is clear that diverse somatic mutations that characterize individual cancers suggest the possibility for targeted therapies to be developed for each individual cancer in each patient, our data demonstrate that colorectal cancers, on average, show few differences based on tumor location. This observation could have important clinical implications in terms of prognostic analysis, biomarker discovery or drug development.
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